60 Degrees Pharmaceuticals Files 8-K
Ticker: SXTPW · Form: 8-K · Filed: Jun 27, 2024 · CIK: 1946563
| Field | Detail |
|---|---|
| Company | 60 Degrees Pharmaceuticals, Inc. (SXTPW) |
| Form Type | 8-K |
| Filed Date | Jun 27, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, exhibits, sec-filing
TL;DR
60 Degrees Pharma filed an 8-K with financial statements and exhibits. No major news.
AI Summary
On June 27, 2024, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or transactions detailed in the provided text. The company is incorporated in Delaware and its principal executive office is located in Washington, D.C.
Why It Matters
This 8-K filing indicates that 60 Degrees Pharmaceuticals, Inc. is providing updated financial statements and exhibits to the SEC, which is a standard regulatory requirement.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any specific new risks or material events.
Key Numbers
- 001-41719 — SEC File Number (Identifies the company's filing with the SEC.)
- 45-2406880 — IRS Employer Identification Number (Company's tax identification number.)
Key Players & Entities
- 60 DEGREES PHARMACEUTICALS, INC. (company) — Registrant
- June 27, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Washington, D.C. (location) — Principal Executive Office Location
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits as of June 27, 2024.
When was this report filed?
This report was filed on June 27, 2024.
In which state is 60 Degrees Pharmaceuticals, Inc. incorporated?
60 Degrees Pharmaceuticals, Inc. is incorporated in Delaware.
What is the address of the registrant's principal executive office?
The address of the registrant's principal executive office is 1025 Connecticut Avenue NW Suite 1000, Washington, D.C. 20036.
Does this filing report any specific material events?
Based on the provided text, this filing primarily concerns financial statements and exhibits and does not detail any specific material events.
Filing Stats: 570 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-06-27 17:06:54
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 per share SXTP The Nasdaq Stock Mar
Filing Documents
- ea0208661-8k_60degrees.htm (8-K) — 33KB
- ea0208661ex99-1_60degrees.htm (EX-99.1) — 24KB
- 0001213900-24-056728.txt ( ) — 280KB
- sxtp-20240627.xsd (EX-101.SCH) — 4KB
- sxtp-20240627_def.xml (EX-101.DEF) — 26KB
- sxtp-20240627_lab.xml (EX-101.LAB) — 36KB
- sxtp-20240627_pre.xml (EX-101.PRE) — 25KB
- ea0208661-8k_60degrees_htm.xml (XML) — 6KB
01. Other Events
Item 8.01. Other Events. On June 27, 2024, 60 Degrees Pharmaceuticals, Inc. (the "Company") issued a press release announcing that it enrolled its first patient in its clinical trial of tafenoquine for Babesiosis at Tufts Medical Center, which is the first and only study of its kind. The Company's press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information set forth under this Item 8.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial
Item 9.01 Financial (d) Exhibits. The following exhibits are being filed herewith: Exhibit No. Description 99.1 Press Release of 60 Degrees Pharmaceuticals, Inc. dated as of June 27, 2024. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 60 DEGREES PHARMACEUTICALS, INC. Date: June 27, 2024 By: /s/ Geoffrey Dow Name: Geoffrey Dow Title: Chief Executive Officer and President 2